CFG
REGN icon

Clayton Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Clayton Financial Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-107
Closed -$82.7K – 459
2026
Q1 		$82.7K Hold
107
– – 0.04% 110
2025
Q4 		$82.6K Buy
+107
New +$72.7K 0.04% 118

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Clayton Financial Group's REGN Position: Q2 2026 in Review

Clayton Financial Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 107 shares — an estimated $82.7K sold.

Clayton Financial Group first reported a position in REGN in Q4 2025 and held it in 2 quarters. The position peaked at $82.7K in Q1 2026. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Clayton Financial Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Clayton Financial Group sold 107 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $82.7K.
  • Clayton Financial Group first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Clayton Financial Group's Regeneron Pharmaceuticals position peaked at $82.7K in Q1 2026.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Clayton Financial Group's 13F filing for Q2 2026, filed 20 Jul 2026.